Clostridioides difficile: Prevention and Microbiome-Based Treatment

Clostridioides difficile infection (CDI) is the most common healthcare-associated infection in the United States, causing approximately 500,000 infections and 29,000 deaths annually. Its pathogenesis is fundamentally a microbiome disease — CDI cannot establish in a fully intact microbiome, and restoration of microbial diversity is the most effective intervention for recurrent disease.

Pathogenesis: A Microbiome Story

C. difficile requires antibiotic disruption of colonization resistance to establish infection. Key protective commensals — Clostridium scindens (converts primary to secondary bile acids), Bacteroides species, and butyrate producers — are depleted by antibiotics, removing competitive exclusion and bile acid-mediated spore germination inhibition. The risk of CDI correlates directly with degree of microbiome disruption.

Primary Prevention: Probiotic Evidence

Prophylactic probiotics during antibiotic courses reduce CDI risk by approximately 60%. The strongest evidence supports L. rhamnosus GG and S. boulardii CNCM I-745 (Johnston et al., Ann Intern Med, 2012). B. longum W11 provides additional competitive exclusion against C. difficile colonization through barrier reinforcement and pathobiont suppression — making it a rational component of perioperative and peribiotic prophylaxis.

Fecal Microbiota Transplantation for Recurrent CDI

FMT is the most effective treatment for recurrent CDI, with efficacy rates of 85-90% for first FMT — far exceeding vancomycin (20-30% for third recurrence). The FDA approved the first microbiome drug (Vowst, Firmicutes-enriched oral FMT capsule) in 2023, followed by Rebyota (enema-based). van Nood et al. (NEJM, 2013) established the RCT foundation with 81% resolution after single FMT versus 31% with vancomycin.

Post-CDI Microbiome Restoration

Survivors of CDI have significantly impaired microbiome diversity for months to years post-infection. Targeted probiotic supplementation focused on butyrate producers and Bifidobacterium species supports long-term recovery. Avoidance of unnecessary antibiotics and PPIs are key secondary prevention strategies. See our antibiotic stewardship article.

Related: Probiotics in Clinical Practice · Bifidobacterium longum in Clinical Settings